FACT: The National Institutes of Health holds a patent on the therapeutic uses of cannabinoids, including CBD.
In 1998, a team of scientists, acting for the National Institutes of Health, applied for a patent with the US Patent Office that demonstrated that they believed that cannabinoids have medicinal value.
Co-authored by Nobel Laureate Julius Axelrod, Patent #6,630,507 was awarded to the National Institutes of Health in 2003, just five years after it was filed. This patent is titled, “Cannabinoids as antioxidants and neuroprotectants.”
FACT: The NIH acknowledges the therapeutic properties and potential uses of CBD.
Officially coined in our industry as “the ‘507 patent,” this document describes the potential therapeutic values of cannabinoids. It describes cannabidiol (CBD) in particular as being a potent antioxidant – more powerful than either vitamin C and vitamin E. CBD is also described as possibly acting with neuroprotective properties, meaning the NIH believes it may protect the brain and nervous system from damage due to blunt-force head trauma, or brain damage from strokes.
The patent also describes CBD as being extremely non-toxic, with zero possibility of an overdose, and no damage demonstrated while taking “large, acute doses” of 700mg CBD/day (which is many times more CBD than most people would desire to ingest on a daily basis).
FACT: This patent flies in the face of the Schedule I status of cannabis, which defines cannabis as having “no medical value.”
The US government doesn’t officially recognize the medical potential of marijuana, at least in part because the studies about its potential therapeutic benefits have been small, and there have been no large-scale clinical trials on the plant as of yet. However, certain components of cannabis have already been made into pharmaceutical drugs for decades, like Marinol, which is a manufactured version of THC used to treat chemotherapy symptoms.
FACT: The ‘507 patent also means anyone wanting to develop a pharmaceutical drug using CBD would have to receive a license from the NIH to do so.
Fortunately, we have that covered. There are several joint venture’s with KannaLife Sciences, a publicly traded company, which includes both exclusive and non-exclusive license agreements with the NIH to develop CBD into viable products, like our high CBD Hemp Oils. This is yet another way that we are working towards a future in which cannabinoids are viewed as the true therapeutic powerhouses emerging research indicates they are.
FACT: Contrary to popular belief, this patent isn’t for medical marijuana.
The ‘507 patent covers the potential medical use of non-psychoactive compounds in cannabis, particularly CBD. The ‘507 patent specifically avoids psychotropic cannabinoids (like THC).
FACT: The ‘507 Patent is among the strongest cases for our CBD business model.
Legitimacy is critical in this world. Operating with the knowledge that one of the most venerable institutions in the world has cataloged the many potential benefits of CBD motivates every business decision we make.